← Back to Treatments
🏅 FDA Orphan Designation

Neutrexin

Trimetrexate glucuronate

Manufacturer: Medimmune Oncology, Inc.

Indicated for:
Adenovirus infection in immunocompromised patientsOrphanLymphoid interstitial pneumonia

FDA-Approved Indications (2)

Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfa…

Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfa…

Population: immunocompromised patients

Indications & Usage

Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.

💙 Support Programs

View all →
Neutrexin
Medimmune Oncology, Inc.
Neutrexin
Medimmune Oncology, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.